Adamis Pharmaceuticals Corporation [ADMP] stock is up 0.99 while the S&P 500 has risen 0.39% on Thursday, 11/19/20. While at the time of this article, ADMP ATR is sitting at 0.07, with the beta value at 2.03. This stock’s volatility for the past week remained at 9.49%, while it was 8.21% for the past 30-day period. ADMP has risen $0.01 from the previous closing price of $0.40 on volume of 5.38 million shares.
On 16, November 2020, Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI. According to news published on Yahoo Finance, Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Adamis’ ZIMHI™ high dose naloxone injection product for the treatment of opioid overdose. The CRL stated that the FDA determined it cannot approve the NDA in its present form and provided recommendations needed for resubmission.
Analyst Birdseye View:
The most recent analyst activity for Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] stock was on February 27, 2020, when it was Downgrade with a Neutral rating from Dawson James. Before that, on May 13, 2020, Maxim Group Recapitulated a Buy rating and elevated its amount target to $1.50. On November 26, 2019, Raymond James Downgrade a Mkt perform rating. On July 16, 2019, B. Riley FBR Downgrade a Sell rating and decreased its price target from $1.90 to $1.10. On November 12, 2018, B. Riley FBR Downgrade a Neutral rating and decreased its price target to $2.50. On May 11, 2018, Maxim Group Reiterated a Buy rating and boosted its amount target on this stock to $10. On March 23, 2018, B. Riley FBR Inc. Reiterated a Buy rating and boosted its target amount on this stock from $6.25 to $7.50. On December 05, 2017, Maxim Group Reiterated a Buy rating and improved its amount target to $14.
In the past 52 weeks of trading, this stock has oscillated between a low of $0.27 and a peak of $1.51. At the most recent market close, shares of Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] were valued at $0.41.
This publicly-traded organization’s revenue is $129,321 per employee, while its income is -$171,385 per employee. This company’s Gross Margin is currently 12.00%, its Pretax Margin is -135.44, and its Net Margin is -132.53. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -54.46, -70.85, -67.13 and -69.60 respectively.
The Principal structure of this organization shows its whole liability to whole principal at 10.17 and the whole liability to whole assets at 8.28. It shows enduring liability to the whole principal at 3.69 and enduring liability to assets at 0.03 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.3898 points at 1st support level, the second support level is making up to 0.3729. But as of 1st resistance point, this stock is sitting at 0.4208 and at 0.4349 for 2nd resistance point.
Adamis Pharmaceuticals Corporation [ADMP] reported its earnings at -$0.1 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.05/share signifying the difference of -0.05 and -100.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.15 calling estimates for -$0.08/share with the difference of -0.07 depicting the surprise of -87.50%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] is 1.30. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.86. Now if looking for a valuation of this stock’s amount to sales ratio it’s 1.69 and it’s amount to book ratio is 1.20.
The most recent insider trade was by Hopkins Robert O, Chief Financial Officer, and it was the sale of 20000.0 shares on Sep 29. Marguglio David J., the SVP and Chief Business Officer, completed a sale of 20000.0 shares on Sep 29. On Aug 18, Marguglio David J., SVP and Chief Business Officer, completed a sale of 8749.0 shares.